Next Article in Journal
The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes
Previous Article in Journal
Clinical Importance of Epstein–Barr Virus-Associated Gastric Cancer
Previous Article in Special Issue
mTOR Cross-Talk in Cancer and Potential for Combination Therapy
Open AccessEditorial

Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting

School of Biochemistry & Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland
Division of Cancer and Genetics, Cardiff University, Heath Park, Cardiff CF14 4XN, UK
Author to whom correspondence should be addressed.
Cancers 2018, 10(6), 168;
Received: 23 May 2018 / Accepted: 24 May 2018 / Published: 30 May 2018
(This article belongs to the Special Issue mTOR Pathway in Cancer)
This special issue on mammalian target of rapamycin (mTOR) explores the importance of mTOR in cell growth control and cancer. Cancer cells often exploit mTOR as a mechanism to enhance their capacity to grow. While protein synthesis is by far the best-characterized mTOR-driven process, this special issue also describes a wider array of mTOR-driven biological processes that cancer cells benefit from, including autophagy, cell cycle control, metabolic transformation, angiogenic signaling, and anabolic processes such as nucleotide biosynthesis and ribosomal biogenesis. Other areas of mTOR signaling covered in these reviews delve into cell migration, inflammation, and regulation of transcription factors linked to cancer progression. View Full-Text
Keywords: mTOR; cancer mTOR; cancer
MDPI and ACS Style

Murray, J.T.; Tee, A.R. Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting. Cancers 2018, 10, 168.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop